Node Positive or High Risk Node negative Triple Negative Breast

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

November 22, 2017

  • Clinical Trial Information

    Trial Contact: Jobson, Gillian S; Morales, Leticia; Pelley, Jennifer

  • IRB No: NRG-BR003

    Protocol Abbrev: NRG-BR003

    Principal Investigator: Nikita Chandrakant Shah, MD

    Sub Investigators: Mamounas, Eleftherios MD; Moroose, Rebecca MD; Rostorfer, Regan MD; Cuesta, Ana MD

    Phase: Drug: Phase III

    Age Group: Adult

    Treatment: Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin

    Applicable Disease Sites: Breast cancer

    Therapies Involved: Chemotherapy

    ClinicalTrials.gov ID: NCT02488967

  • Objective

    To determine if the addition of carboplatin will improve IDFS

  • Key Eligibility

    Early stage triple negative breast cancer